Related Experiment Video
Updated: Jul 7, 2026

Automated Imaging and Analysis for the Quantification of Fluorescently Labeled Macropinosomes
Published on: August 24, 2021
Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells
Shinpei Nishimura1, Shunsuke Takahashi, Hiromi Kamikatahira
1Department of Molecular Cell Function, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, 5-1 Ohe-honmachi, Kumamoto 862-0973, Japan.
Abstract:
Ligand-directed delivery of agents to leukemia and lymphoma cells has the potential to yield new mechanistic disease insights and targeted therapies. Here we set out to target the macropinocytotic pathway with a combinatorial approach. From the screening of acute T-lymphoblastic leukemia Molt-4 cells with a random phage-display peptide library, we isolated a phage displaying the sequence CAYHRLRRC. This peptide contains a lymph node-homing motif (Cys-Ala-Tyr) and a cell-penetrating motif (Arg-Leu-Arg-Arg). Binding of this ligand-directed phage to a large panel of leukemia/lymphoma cells and to patient-derived samples was much higher than to non-leukemia control cells. CAYHRLRRC phage internalization into Molt-4 cells is both energy- and temperature-dependent. Flow cytometry with fluorescein-labeled peptide and endocytosis blocking with specific inhibitors revealed that CAYHRLRRC is indeed taken up through macropinocytosis in Molt-4 and K562 human leukemia cells. Unexpectedly, the cell surface receptor for the CAYHRLRRC peptide is not a heparan sulfate proteoglycan as it would be predicted for other cell-penetrating peptides. Confirming this interpretation, a CAYHRLRRC-directed peptidomimetic-induced cell death in all the leukemia and lymphoma cells was evaluated, whereas a control transactivator of transcription protein (tat)-directed proapoptotic peptidomimetic was non-selective. In summary, the targeting peptide CAYHRLRRC is selectively internalized through macropinocytosis in leukemia and lymphoma cells and has potential as a drug lead for ligand-directed anti-leukemia therapies.
Insights
Researchers identified a novel peptide, CAYHRLRRC, that selectively targets leukemia and lymphoma cells via macropinocytosis. This peptide shows promise for developing targeted therapies against these blood cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Ligand-directed delivery offers potential for novel leukemia and lymphoma therapies.
- Targeting cellular pathways like macropinocytosis is a key strategy in drug development.
Purpose of the Study:
- To identify and characterize a novel ligand for targeting leukemia and lymphoma cells.
- To explore the potential of this ligand for developing targeted anti-cancer therapies.
Main Methods:
- Phage-display screening of acute T-lymphoblastic leukemia Molt-4 cells to isolate targeting peptides.
- Flow cytometry and endocytosis inhibition assays to confirm cellular uptake mechanism (macropinocytosis).
- Evaluation of peptidomimetics derived from the identified peptide for selective cell death induction.
Main Results:
- A peptide, CAYHRLRRC, was isolated with high binding affinity for leukemia/lymphoma cells and patient samples.
- CAYHRLRRC is internalized via energy- and temperature-dependent macropinocytosis in leukemia cell lines.
- CAYHRLRRC-directed peptidomimetics induced selective cell death in leukemia and lymphoma cells, unlike a control peptidomimetic.
Conclusions:
- The peptide CAYHRLRRC is selectively internalized by leukemia and lymphoma cells through macropinocytosis.
- CAYHRLRRC represents a promising drug lead for developing ligand-directed therapies against leukemia and lymphoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway
